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Introduction
Diminished ovarian reserve (DOR) is often associated with 
poor ovarian stimulation response, a high cancellation rate, 
and a significant decline in pregnancy rate during in vitro 
fertilization (IVF) cycle. DOR is characterized by poor fertility 
outcomes even when assisted reproductive techniques are 
used and represents a major challenge in reproductive medi-
cine [1]. Poor response to ovarian stimulation usually indicates 
decreased follicular response, resulting in a reduced number 
of retrieved oocytes [2]. The European Society of Human Re-
production and Embryology (ESHRE) consensus defines poor 
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Objective
This study aimed to identify factors that affect in vitro fertilization (IVF) outcomes in women with diminished ovarian 
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Methods
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anti-Müllerian hormone level of <1.1 ng/dL or serum follicle-stimulating hormone level of ≥20 mIU/mL. Total 96 cycles in 50 
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ovarian response (POR) to ovarian stimulation as, “when at 
least two of the following three characteristics are present: (1) 
advanced maternal age (≥40 years) or any of the risk factors 
for poor ovarian responders, (2) a previous POR (≤3 oocytes 
with a conventional stimulation protocol), and (3) an abnor-
mal ovarian reserve test result (i.e., antral follicle count [AFC] 
of <5–7 follicles or anti-Müllerian hormone [AMH] level of 
<0.5–1.1 ng/mL),” as in the Bologna criteria. Two episodes 
of POR after maximal stimulation are sufficient to define a 
patient as a poor responder in the absence of advanced ma-
ternal age or an abnormal ovarian reserve test result [2]. 
Although DOR has been one of the main factor results in 
POR, there has been few studies which had evaluated dif-
ferences among causes of DOR. A recent retrospective case-
control study showed DOR by surgery for endometrioma had 
better response to controlled ovarian stimulation comparing 
to idiopathic group [3]. Regardless of the causes, though the 
resulting DOR is the same, factors that could predict better 
IVF outcome might exist. Since DOR is a risk factor for POR, it 
may be important to know a group of patient who will show 
better IVF outcome to avoid repeated prolonged, tired, high-
cost IVF procedures. The aim of this study was to evaluate 
factors that affect IVF outcomes in women with DOR.
Materials and methods
1. Study population
A retrospective cohort study was conducted by using data on 
IVF cycles performed in a single IVF center of a tertiary hos-
pital. From September 2010 to January 2015, 99 IVF cycles 
in 52 patients with DOR were included. Although there has 
been consensus on the concept of DOR, the definition has 
been heterogeneously made. We defined DOR based on the 
Bologna ESHRE consensus of PORs [2], and serum follicle-
stimulating hormone (FSH) level over 20 mIU/mL, the level 
which has been traditionally used as margin at our clinic. 
DOR was defined as a serum AMH level of <1.1 ng/dL, which 
was measured within 6 months to 1 year of the IVF cycle in 
this study, or a serum FSH level of >20 mIU/mL, which was 
measured within 1 to 3 months of the IVF cycle [1]. The exclu-
sion criteria were frozen thawing embryo transfer (ET) cycle, 
oocyte donation cycle, fertility preservation cycle, IVF cycles 
in patients whose ovarian reserve test (serum AMH level) was 
performed at least 1 year prior, and serum FSH levels mea-
sured at least 6 months prior. After excluding the cycles for 
embryo cryopreservation (3 cycles in 2 patients) for fertility 
preservation, 96 cycles in 50 patients were examined, finally. 
The causes of DOR were aging (age ≥35 years, without any 
surgical history), previous ovarian surgery, idiopathic factor 
(age <35 years, neither history of ovarian surgery nor chemo-
therapy), and chemotherapy history. The IVF outcomes were 
classified as clinical pregnancy in ET do group, and cancel-
lation in undo group. Clinical pregnancy was defined as an 
intrauterine gestational sac with an embryo showing normal 
cardiac activity confirmed on ultrasonography. Patients with 
cancelled ET were defined as those who had undergone 
oocyte pickup (OPU) but not ET because of unfertilization or 
abnormal fertilization and had no retrieved oocytes or had 
immature oocyte retrieval. Patients with cancelled OPU were 
defined as those who had cancelled OPU due to the absence 
of growing follicles in response to stimulation or premature 
ovulation. The study was approved by the institutional review 
board of the Severance Hospital, Yonsei University College of 
Medicine (4-2016-0152).
2. Stimulation protocols and IVF procedure
The ovarian stimulation was performed according to the con-
dition of each patient by using conventional protocols such 
as gonadotropin releasing hormone (GnRH) agonist long 
protocol, flexible GnRH antagonist protocol, GnRH agonist 
microflare, and ultrashort protocol. In certain cycles, soft stim-
ulation or natural IVF cycle was selected. In conventional pro-
tocols, recombinant FSH (Gonal-F, Serono, Geneva, Switzer-
land; Follitrope, LG Lifescience, Seoul, Korea) with or without 
human menopausal gonadotropin (IVF-M, LG Lifescience) was 
used with luteal long protocol of a GnRH agonist (Decapeptyl 
0.1 mg/day, Ferring; n=16) or the GnRH antagonist protocol 
(Cetrotide 0.25 mg/day, Serono; n=15). The GnRH agonist mi-
croflare protocol (Decapeptyl 0.05 mg/day, Ferring; n=17) or 
the GnRH agonist ultrashort protocol (Decapeptyl 0.1 mg/day, 
Ferring; n=9) was used with the antagonist (Cetrotide 0.25 
mg/day, Serono). The soft stimulation protocol used either 
100-mg/day clomiphene citrate (clomiphene, Youngpoong 
Pharma, Seoul, Korea) or 5 mg/day letrozole (Femara, Novar-
tis, Basel, Switzerland) with 150 IU/day human menopausal 
gonadotropin (IVF-M, LG Lifescience) and the antagonist (Ce-
trotide 0.25 mg/day, Serono; n=29). The natural IVF cycle was 
performed by using the antagonist (Cetrotide 0.25 mg/day, 
Serono), with or without human menopausal gonadotropin 
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Age (yr) 40 (28–46) 35 (31–42)a) 35 (29–45)a) 40 (29–42) 0.038b)
<35 11 (21.57) 5 (45.5) 12 (44.44) 2 (40.0) 0.092
35–39 14 (26.9) 4 (36.4) 6 (22.22) 0
40≤ 27 (51.9) 2 (18.2) 8 (29.63) 3 (60.0) 
Serum AMH (ng/mL) 0.75 (0–1.26) 0.84 (0.15–1.26) 0.35 (0–1.26) 0.15 (0–0.89) 0.113b)
Serum FSH (mIU/mL) 11.6 (5.0–60.8) 11.9 (5.0–39.4) 19.8 (6.0–76.7)a),c) 18.6 (6.5–76.7) 0.018
Serum E2 (pg/mL) 65.27±85.13 42.45±23.51 59.52±71.27 30.0±22.77 0.832
Total AFC (n) 4.61±2.19c) 7.09±2.63 3.93±2.91c) 3.20±1.30c) 0.005
Total Gn dose (IU) 2,421.63±1814.67 3,013.63±1,373.88 1,319.44±1,334.24a),c) 180±268.33a),c) 0.001
Stimulation days 10.69±3.83 10.81±1.66 11.30±5.80 13.6±4.39 0.563
P eak E2 on day of hCG 
administration (pg/mL)
1,406.9±1051.93 1,870.82±1,581.66 577.35±493.18 442.50±208.60a) 0.031
Total oocytes retrieved (n) 3 (1–11) 4 (2–6) 1 (0–5)a),c) <0.0001b)
No. of MII (n) 2 (0–8) 2 (0–5) 1 (0–2)a),c) <0.0001b)
No. of 2PN (n) 2 (0–7) 2 (0–5) 0 (0–1)a),c) <0.0001b)
CES 40.02±26.88 41.82±27.63 0a),c) 0.016
TMSC (million) 137.97±154.04 213.57±182.13 114.70±128.59 0.486
COH protocol 0.002
Conventional stimulation 34 (65.4) 10 (46.4) 13 (46.4) 0
Soft/natural stimulation 18 (34.6) 1 (53.6) 15 (53.6) 5 (100) 
Cause of infertility 0.305
Unexplained 22 (42.3) 5 (45.5) 17 (63) 1 (20)
EMS 21 (40.4) 5 (45.5) 8 (29.6) 4 (80)
Male factor 9 (17.3) 1 (9.1) 2 (7.4) 0 (0)
C ause of diminished ovarian 
reserve
0.01
Aging 33 (65.4) 3 (27.3) 11 (39.3) 3 (60)
36 (57.1) 14 (42.4)
Previous ovarian surgery 9 (15.4) 5 (45.5) 4 (14.3) 0 (0)
14 (22.2) 4 (12.1)
Idiopathic 10 (19.2) 3 (27.3) 9 (33.3) 1 (20)
13 (20.6) 10 (30.3) 
Previous chemotherapy 0 (0) 0 (0) 4 (14.3) 1 (20)
0 (0) 5 (15.2)
Data are presented as median (range), mean±standard deviation, or number (%).
ET, embryo transfer; OPU, oocyte pickup; AMH, anti-Müllerian hormone; FSH, follicle-stimulating hormone; E2, estradiol; AFC, antral follicle 
count; Gn, gonadotropin; hCG, human chorionic gonadotropin; MII, metaphase II; PN, pronuclei; CES, cumulative embryo score; TMSC, total 
motile sperm count; COH, controlled ovarian hyperstimulation; EMS, endometriosis.
a)Comparison with the non-pregnancy group by post hoc analysis; b)Kruskal-Wallis test was performed, and data are expressed as median (range); 
c)Comparison with the clinical pregnancy group by post hoc analysis.
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(IVF-M, LG Lifescience; n=10). When one or more leading fol-
licles reached a mean diameter of ≥18 mm, 250 μg of recom-
binant human chorionic gonadotropin (rhCG; Ovidrel, Serono) 
was given. The oocytes were retrieved around 34 to 36 hours 
after the rhCG injection. The oocytes were inseminated by 
using the conventional method (n=47) or via intracytoplasmic 
sperm injection (n=31), depending on the quality of the gam-
etes. The embryos were transferred 3 days after the retrieval 
of the oocyte. Luteal phase support was performed by using 
either a daily dose of 50 mg of progesterone in oil (Progest, 
Samil, Seoul, Korea) or 800 mg/day micronized progesterone 
vaginal suppositories (Utrogestan, Brussels, Belgium). 
3. Statistical analyses
Data are presented as mean±standard deviation for continu-
ous variables, and as numbers and percentages for categori-
cal variables. The baseline characteristics were compared be-
tween the non-pregnancy and clinical pregnancy groups, and 
between the ET and OPU cancelled groups in ET do and undo 
cycles, by using one-way analysis of variance for the normally 
distributed continuous variables, with post hoc analysis using 
the Bonferroni procedure. A chi-square test was performed 
for the categorical variables. After the normality tests, the 
Kruskal-Wallis test was performed for the non-parametrically 
distributed variables. The univariate and multivariate logistic 
regression analyses were performed to examine factors that 
could influence clinical pregnancy and cycle cancellation, re-
spectively. Logistic models were built based on the goodness-
of-fit of the model and the multicollinearity of the factors. 
The factors with a P-value of <0.1 in the univariate analysis 
were included in the logistic model. Data were analyzed by 
using IBM SPSS ver. 20.0 (IBM Corp., Armonk, NY, USA). A P-
value of <0.05 was considered statistically significant.
Results
A total 96 IVF cycles in 50 patients were analyzed. Of these 
Table 2. Factors that affect clinical pregnancy in women with diminished ovarian reserve
　
Univariate Multivariate (model 1) Multivariate (model 2)
OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value
Age (yr) 0.87 (0.75–1.01) 0.063
Serum AMH (ng/mL) 6.83 (0.77–60.86) 0.085 4.91 (0.26–91.8) 0.287
Serum FSH (mIU/mL) 0.98 (0.94–1.03) 0.476
Total AFC (n) 1.35 (1.07–1.70) 0.013 1.49 (1.03–2.14) 0.034
Peak E2 (pg/mL) 1 (1.0–1.0) 0.308
Retrieved oocytes, total (n) 1.14 (0.89–1.45) 0.304
Number of MII (n) 1.16 (0.83–1.63) 0.397
Number of 2PN (n) 1.46 (0.97–2.20) 0.071 1.18 (0.75–1.86) 0.484 1.52 (0.96–2.39) 0.075
CES 1.00 (0.98–1.03) 0.79
Cause of infertility
Unexplained 1
EMS 1.507 (0.38–6.06) 0.563
Male factor 0.932 (0.94–9.20) 0.952
C ause of diminished ovarian reserve
Aging 1 1 1
Previous ovarian surgery 9.23 (1.60–53.15) 0.013 10.17 (1.46–70.84) 0.019 10.85 (1.05–11.71) 0.045
Idiopathic+previous chemotherapy 3.6 (0.56–23.21) 0.178 2.60 (0.34–19.67) 0.355 9.06 (0.77–106.66) 0.08
Model 1 was adjusted for the total AFC, number of 2PN, and cause of diminished ovarian reserve. Model 2 was adjusted for the same vari-
ables used in model 1, except for AFC, which was substituted with serum AMH level.
OR, odds ratio; CI, confidence interval; AMH, anti-Müllerian hormone; FSH, follicle-stimulating hormone; AFC, antral follicle count; E2, estra-
diol; MII, metaphase II; PN, pronuclei; CES, cumulative embryo score; EMS, endometriosis.
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cycles, 64 (66.6%) entered ET and 11 (11.5%) had achieved 
clinical pregnancy after IVF-ET. The mean age of the included 
cases was 37.5±4.9 years. The mean serum AMH and FSH 
levels were 0.6±0.4 ng/dL and 20.0±17.7 mIU/mL, respec-
tively. The clinical characteristics of the IVF cycles included are 
shown in Table 1. Although serum AMH levels did not show 
significant differences between the groups, AFC showed a 
significant difference, especially between clinical pregnancy 
group and the other groups, respectively (P=0.005). The 
controlled ovarian hyperstimulation protocols showed signifi-
cantly different among groups, however, it may be reflecting 
the degree of DOR and other characteristics. Although the 
distribution of the causes of infertility was similar between the 
groups, the cause of DOR significantly differed (P=0.01). In 
clinical pregnancy group, the proportion of women with previ-
ous ovarian surgery was relatively higher than that in the non-
pregnancy group. In the comparison between the ET do and 
undo group, the cause of DOR significantly differed (P=0.06, 
not shown in Table 1) with higher percentage of women with 
idiopathic and causes related to previous chemotherapy. None 
of the women with DOR caused by previous chemotherapy 
has undergone ET, but all had cycle cancellation.
In a simple comparison, the analyses showed that the total 
AFC and cause of DOR were significantly related to clinical 
pregnancy (Table 2). Age, serum AMH level, and number of 
2PN showed an association with borderline significance. Lo-
gistic model 1 showed significant associations of AFC (odds 
ratio [OR], 1.49; 95% confidence interval [CI], 1.03 to 2.14; 
P=0.034) and previous ovarian surgery (OR, 10.17; 95% CI, 
1.46 to 70.84; P=0.019) with clinical pregnancy. In model 2, 
the adjusted variables included serum AMH level, number 
of 2PN, and the causes of DOR. Ovarian surgery history re-
mained significantly positively associated with clinical preg-
nancy (OR, 10.85; 95% CI, 1.05 to 111.71; P=0.045).
In terms of cycle cancellation, the univariate analysis re-
vealed significant relationships between age, serum AMH 
level, serum FSH level, total AFC, peak estradiol (E2) level on 
the day hCG was administered, DOR due to previous chemo-
therapy, and idiopathic cause (Table 3). However, the logistic 
models with adjusted variables showed associations with 
borderline significance between the cause of DOR and cycle 
cancellation due to idiopathic and previous chemotherapy-
related causes (Table 4). The logistic models were constructed 
with adjusted variables, including total AFC, peak E2 level 
on the day of hCG administration, controlled ovarian hyper-
stimulation protocol, the cause of DOR, and serum FSH (model 
1) or AMH level (model 2). Model 1 showed positive associa-
tions between peak E2 level on the day of hCG administration 
(OR, 6.22; 95% CI, 0.81 to 47.63; P=0.079) (data not shown 
in Table 4) and DOR caused by idiopathic and previous che-
motherapy-related causes (OR, 3.76; 95% CI, 0.83 to 17.04; 
P=0.086) (Table 4), although not statistically significantly. 
Model 2 also showed similar results in that peak E2 level on 
the day of hCG administration (OR, 5.21; 95% CI, 0.86 to 
31.8; P=0.073) (data not shown in Table 4) and DOR caused 
by idiopathic and previous chemotherapy-related causes (OR, 
3.15; 95% CI, 0.84 to 11.84; P=0.09) (Table 4) were positively 
but not significantly associated with cycle cancellation.





OR (95% CI) P-value
Age (yr) 0.91 (0.83–1.0) 0.042
Serum AMH (ng/mL) 0.28 (0.09–0.87) 0.028
Serum FSH (mIU/mL) 1.05 (1.02–1.08) 0.001
Total AFC (n) 0.81 (0.66–0.99) 0.035
Peak E2 (pg/mL) 0.99 (0.99–1.0) 0.002
<200 13.0 (2.7–62.72) 0.001
≥200 but <800 4.18 (1.39–12.54) 0.011
≥800 1
COH protocol
GnRH agonist long 0 (0–0) 0.998
Antagonist 0.44 (0.09–2.28) 0.330
Ultrashort 0.19 (0.03–1.43) 0.107
Soft stimulation 0.62 (0.15–2.68) 0.524
GnRH agonist microflare 0.28 (0.054–1.43) 0.126
Natural/modified natural 1
C ause of diminished ovarian 
reserve
Aging 1
Previous ovarian surgery 0.81 (0.23–2.92) 0.751
Id iopathic and previous 
chemotherapy
3.1 (1.16–7.8) 0.023
OR, odds ratio; CI, confidence interval; AMH, anti-Müllerian hor-
mone; FSH, follicle-stimulating hormone; AFC, antral follicle count; 
E2, estradiol; COH, controlled ovarian hyperstimulation; GnRH, go-
nadotropin releasing hormone; EMS, endometriosis.
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Discussion
Our study showed a possible significant association between 
the cause of DOR and IVF outcome, especially in relation to 
histories of ovarian surgery and chemotherapy. A notable 
finding is that women with DOR caused by previous ovar-
ian surgery may show higher possibility of clinical pregnancy 
than those with DOR of other causes. However, among the 
women with low ovarian reserve, those with DOR caused by 
chemotherapy could have greater risk of cycle cancellation, 
not permitting even oocyte retrieval, than those with DOR 
of other causes. Our study focused on the fact that all cases 
may have decreased ovarian reserve but that different causes 
may act differently on the IVF outcome, which may mean that 
each patient requires individualized counseling and motiva-
tion.
Previous studies suggested predictive factors for clinical 
pregnancy in IVF/intracytoplasmic sperm injection cycles of 
DOR, such as serum AMH level and AFC on ultrasonography 
[4,5]. A study reported that patients with serum AMH levels 
of >0.4 ng/dL showed significantly lower liver birth rates 
than those with higher AMH levels [6]. They also suggested 
that every 0.1 ng/dL increase in AMH levels can cause a cor-
responding increase in clinical pregnancy rate. In contrast to 
the previous studies, our study showed that serum AMH level 
was not associated with clinical pregnancy or cycle cancella-
tion in women with low ovarian reserve. In terms of the cause 
of DOR, few studies have shown a significant association with 
pregnancy outcome [7,8]. Age and prior chemotherapy have 
been suggested as related factors. However, evidence is insuf-
ficient to prove that idiopathic premature ovarian insufficien-
cy, repeated ovarian surgery, or other possible factors such as 
autoimmune diseases can affect IVF outcomes.
Several studies reported a significant decrease in ovarian 
response to IVF in cancer patients who had undergone che-
motherapy [9,10]. In a cohort study, regardless of the type 
of cancer, response to gonadotropins and the number of 
oocytes retrieved were significantly decreased in the post-
chemotherapy group [10]. Our study shows similar results as 
the previous study of Chan et al. [10]. which showed higher 
cancellation rates in post-chemotherapy patients than in che-
motherapy-naïve patients. However, while the previous study 
showed low AFC as a factor related to cycle cancellation, 
our study showed an association with borderline significance 
between peak E2 level and chemotherapy-related cycle can-
cellation. The difference may be caused by the small number 
of patients included, as only three post-chemotherapy cases 
were included.
Our study clearly shows a significant relationship between 
the cause of poor ovarian reserve and IVF outcome. However, 
its retrospective design and the small number of participants 
included in the analyses remain major limitations of the study. 
Heterogeneous character of the participants may provide as 
bias, so that the interpretation needs to be cautious. More-
over, as the IVF cycles included were intentioned to result in 
conception, cycles for fertility preservation such as oocyte 
cryopreservation could yield different results in terms of pre-
dictive factors of ovarian response.
In conclusion, the present study shows that women with 
DOR caused by previous ovarian surgery may benefit from as-
sisted reproductive technologies. Furthermore, counseling pa-
tients with DOR who previously received gonadotoxic agents 
Table 4. Adjusted ORs of the risk factors of cycle cancellation
Cause of diminished ovarian reserve Adjusted OR (95% CI) P-value 
Model 1 Aging 1
Previous ovarian surgery 1.93 (0.29–12.99) 0.498
Idiopathic and previous chemotherapy 3.76 (0.83–17.04) 0.086
Model 2 Aging 1
Previous ovarian surgery 2.05 (0.34–12.29) 0.433
Idiopathic and previous chemotherapy 3.15 (0.84–11.84) 0.09 
Model 1 of cycle cancellation was adjusted for peak estradiol (<200 pg/dL, ≥200 but <800 pg/dL, and ≥800 pg/dL), serum follicle-stimulating 
hormone level, total antral follicle count, controlled ovarian hyperstimulation protocol (gonadotropin releasing hormone agonist long, antago-
nist, ultrashort, soft stimulation, gonadotropin releasing hormone agonist microflare, and natural/modified natural); Model 2 of cycle cancel-
lation was adjusted for the same variables used in model 1, except for serum follicle-stimulating hormone level, which was substituted with 
serum anti-Müllerian hormone level.
OR, odds ratio; CI, confidence interval. 
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should be performed with caution, as they may show reduced 
efficacy and higher risk of IVF cycle cancellation. Fertility pres-
ervation may get stressed more, in certain patient groups, 
who treat with gonadotoxic agents.  
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